- Home
- NBBK vs FTH Comparison
NBBK vs FTH Comparison
Compare NBBK & FTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NBBK | FTH |
|---|---|---|
| Founded | 1892 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 926.5M | 835.7M |
| IPO Year | 2023 | 2021 |
Fundamental Metrics
Financial Performance| Metric | NBBK | FTH |
|---|---|---|
| Price | $22.21 | $25.88 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 14 |
| Target Price | $25.50 | ★ $56.67 |
| AVG Volume (30 Days) | 216.8K | ★ 340.2K |
| Earning Date | 10-21-2026 | 11-13-2026 |
| Dividend Yield | ★ 1.24% | N/A |
| EPS Growth | ★ 25.23 | N/A |
| EPS | ★ 0.90 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $40.00 | N/A |
| Revenue Next Year | $8.51 | N/A |
| P/E Ratio | $25.06 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.84 | $17.50 |
| 52 Week High | $23.47 | $42.14 |
Technical Indicators
Market Signals| Indicator | NBBK | FTH |
|---|---|---|
| Relative Strength Index (RSI) | 44.32 | 35.66 |
| Support Level | $21.52 | $23.47 |
| Resistance Level | $22.72 | $31.37 |
| Average True Range (ATR) | 0.41 | 2.27 |
| MACD | -0.03 | -0.58 |
| Stochastic Oscillator | 39.23 | 21.50 |
Price Performance
Historical ComparisonAbout NBBK NB Bancorp Inc.
NB Bancorp Inc operates as the holding company of Needham Bank. The group's business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations, in commercial real estate and multifamily loans, one- to four-family residential real estate loans, construction and land development loans, commercial and industrial loans, consumer loans, and other related services.
About FTH Faeth Therapeutics Inc. Common Stock
Faeth Therapeutics Inc is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. The company's principal program is PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib in development for endometrial and breast cancer.